Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil Concentration for Preventing Emergence Cough in Nasal Surgery
NCT01291849Phase 4
Key facts
- Status
- Completed
- Start
- Mar 2010
- Countries
- 1
- Sponsor
- Yonsei University
- Modality
- Orthosteric Ligands
- Drugs
- remifentanil
01
Overview
Phase 4, open-label, single-arm trial of remifentanil, sponsored by Yonsei University. Primary endpoints: Incidence of cough and Severity of cough. Started Mar 2010; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
remifentanil for intranasal surgery
Remifentanil TCI targeting a specific effect-site concentration determined by the previous patient's response (Dixon up-and-down method).
03
Who it enrols
Male patients aged 18-60 undergoing ESS or septoplasty, ASA I or II. Excludes BMI > 30, chronic respiratory disease, recent respiratory infection, chronic coughing, significant cardiovascular/hepatic/renal disease, current smokers, and those on opioids or ACEIs.
04
Endpoints
Primary
Incidence of cough
Severity of cough
Beyond the preview
Go deeper on NCT01291849.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01291849.